| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| NF-kappa B p50 Subunit | 8 | 2020 | 42 | 3.860 |
Why?
|
| Brain Neoplasms | 15 | 2023 | 785 | 3.340 |
Why?
|
| NF-kappa B | 7 | 2021 | 465 | 2.720 |
Why?
|
| Glioma | 8 | 2019 | 294 | 2.340 |
Why?
|
| Dacarbazine | 6 | 2018 | 101 | 2.280 |
Why?
|
| Antineoplastic Agents, Alkylating | 6 | 2019 | 135 | 2.240 |
Why?
|
| Glioblastoma | 6 | 2023 | 265 | 2.110 |
Why?
|
| Hydrocephalus | 6 | 2022 | 104 | 1.430 |
Why?
|
| DNA Damage | 6 | 2019 | 371 | 1.330 |
Why?
|
| Genomic Instability | 2 | 2020 | 83 | 1.170 |
Why?
|
| Cerebrospinal Fluid Shunts | 6 | 2022 | 53 | 1.140 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2020 | 288 | 1.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 1277 | 1.010 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2018 | 665 | 0.850 |
Why?
|
| Cell Line, Tumor | 10 | 2021 | 2578 | 0.800 |
Why?
|
| CDC2 Protein Kinase | 1 | 2021 | 46 | 0.740 |
Why?
|
| Spinal Cord Compression | 2 | 2012 | 28 | 0.740 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2020 | 19 | 0.700 |
Why?
|
| Dura Mater | 2 | 2012 | 44 | 0.680 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2020 | 64 | 0.670 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2018 | 603 | 0.670 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2020 | 172 | 0.660 |
Why?
|
| Transcription Factors | 2 | 2018 | 1658 | 0.630 |
Why?
|
| Supratentorial Neoplasms | 1 | 2018 | 10 | 0.630 |
Why?
|
| Cell Cycle | 1 | 2020 | 508 | 0.630 |
Why?
|
| Magnetite Nanoparticles | 1 | 2018 | 27 | 0.620 |
Why?
|
| Dog Diseases | 1 | 2018 | 35 | 0.620 |
Why?
|
| RNA, Long Noncoding | 1 | 2019 | 120 | 0.590 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 130 | 0.550 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2019 | 482 | 0.540 |
Why?
|
| Drug Delivery Systems | 2 | 2018 | 178 | 0.530 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 412 | 0.530 |
Why?
|
| Nanoparticles | 2 | 2018 | 164 | 0.530 |
Why?
|
| Mice | 13 | 2024 | 11812 | 0.510 |
Why?
|
| Animals | 22 | 2024 | 27453 | 0.510 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2015 | 4 | 0.500 |
Why?
|
| Aging, Premature | 1 | 2014 | 6 | 0.490 |
Why?
|
| Binding Sites | 4 | 2021 | 1120 | 0.490 |
Why?
|
| S Phase | 1 | 2015 | 63 | 0.480 |
Why?
|
| Humans | 45 | 2024 | 89500 | 0.480 |
Why?
|
| Promoter Regions, Genetic | 6 | 2021 | 961 | 0.470 |
Why?
|
| DNA Replication | 1 | 2015 | 171 | 0.460 |
Why?
|
| Haploinsufficiency | 1 | 2014 | 65 | 0.450 |
Why?
|
| Brain | 6 | 2022 | 2292 | 0.450 |
Why?
|
| Multiple Myeloma | 1 | 2018 | 331 | 0.450 |
Why?
|
| Transcription Factor RelA | 2 | 2018 | 49 | 0.440 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2007 | 699 | 0.420 |
Why?
|
| Hydrodynamics | 1 | 2022 | 19 | 0.420 |
Why?
|
| Pituitary Neoplasms | 2 | 2019 | 69 | 0.410 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2012 | 24 | 0.410 |
Why?
|
| Mice, Nude | 4 | 2019 | 816 | 0.360 |
Why?
|
| Endoscopy | 3 | 2004 | 351 | 0.350 |
Why?
|
| Signal Transduction | 2 | 2024 | 3392 | 0.350 |
Why?
|
| Convection | 3 | 2018 | 12 | 0.340 |
Why?
|
| Aging | 1 | 2014 | 721 | 0.340 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1668 | 0.330 |
Why?
|
| DNA Methylation | 2 | 2023 | 660 | 0.320 |
Why?
|
| Spinal Neoplasms | 1 | 2008 | 49 | 0.310 |
Why?
|
| Sacrum | 1 | 2008 | 43 | 0.310 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 2323 | 0.310 |
Why?
|
| Epidural Abscess | 1 | 2008 | 3 | 0.310 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2008 | 186 | 0.310 |
Why?
|
| Genetic Therapy | 4 | 2019 | 371 | 0.310 |
Why?
|
| Eyebrows | 1 | 2008 | 10 | 0.310 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2007 | 18 | 0.300 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2007 | 25 | 0.300 |
Why?
|
| Orbit | 1 | 2008 | 39 | 0.300 |
Why?
|
| Alkylation | 2 | 2020 | 31 | 0.300 |
Why?
|
| Lumbar Vertebrae | 1 | 2008 | 152 | 0.290 |
Why?
|
| Craniotomy | 1 | 2008 | 89 | 0.290 |
Why?
|
| Phosphorylation | 3 | 2015 | 1130 | 0.290 |
Why?
|
| Adenoviridae | 2 | 2007 | 349 | 0.280 |
Why?
|
| Gene Transfer Techniques | 1 | 2007 | 153 | 0.280 |
Why?
|
| Serine | 2 | 2020 | 104 | 0.280 |
Why?
|
| Craniopharyngioma | 1 | 2006 | 12 | 0.270 |
Why?
|
| Wilms Tumor | 1 | 2006 | 38 | 0.270 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 3018 | 0.270 |
Why?
|
| Guanine | 1 | 2007 | 207 | 0.270 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2006 | 48 | 0.270 |
Why?
|
| Cisterna Magna | 2 | 2022 | 11 | 0.260 |
Why?
|
| Male | 17 | 2021 | 42438 | 0.260 |
Why?
|
| Intracranial Pressure | 2 | 2022 | 88 | 0.260 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 3228 | 0.250 |
Why?
|
| Staphylococcal Infections | 1 | 2008 | 271 | 0.240 |
Why?
|
| Ventriculostomy | 2 | 2004 | 29 | 0.240 |
Why?
|
| Neurosurgical Procedures | 3 | 2022 | 234 | 0.240 |
Why?
|
| Polymers | 2 | 2018 | 195 | 0.240 |
Why?
|
| Fibroblasts | 2 | 2020 | 758 | 0.240 |
Why?
|
| STAT1 Transcription Factor | 1 | 2024 | 53 | 0.240 |
Why?
|
| Pinealoma | 1 | 2004 | 5 | 0.240 |
Why?
|
| Base Sequence | 2 | 2021 | 2329 | 0.230 |
Why?
|
| Pineal Gland | 1 | 2004 | 15 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2022 | 3462 | 0.230 |
Why?
|
| Sella Turcica | 2 | 2019 | 17 | 0.230 |
Why?
|
| Cellular Senescence | 2 | 2015 | 100 | 0.230 |
Why?
|
| Protein Binding | 3 | 2015 | 1490 | 0.230 |
Why?
|
| Neurosurgery | 1 | 2005 | 103 | 0.230 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2024 | 80 | 0.220 |
Why?
|
| Animals, Newborn | 1 | 2024 | 524 | 0.210 |
Why?
|
| Mice, Knockout | 3 | 2024 | 2003 | 0.210 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2022 | 56 | 0.200 |
Why?
|
| Cell Death | 2 | 2014 | 261 | 0.200 |
Why?
|
| Treatment Outcome | 8 | 2021 | 8200 | 0.200 |
Why?
|
| Otolaryngology | 1 | 2022 | 55 | 0.200 |
Why?
|
| Patient Satisfaction | 2 | 2022 | 460 | 0.190 |
Why?
|
| Female | 14 | 2021 | 46328 | 0.190 |
Why?
|
| Kidney Neoplasms | 1 | 2006 | 523 | 0.190 |
Why?
|
| Ambulatory Care Facilities | 1 | 2022 | 111 | 0.190 |
Why?
|
| Luciferases | 2 | 2015 | 128 | 0.190 |
Why?
|
| Time Factors | 7 | 2021 | 5330 | 0.190 |
Why?
|
| Intracranial Thrombosis | 1 | 2001 | 28 | 0.190 |
Why?
|
| Ubiquitination | 1 | 2020 | 73 | 0.180 |
Why?
|
| Survival Analysis | 2 | 2018 | 1496 | 0.180 |
Why?
|
| DNA Probes | 1 | 2020 | 77 | 0.180 |
Why?
|
| Protein Domains | 1 | 2020 | 135 | 0.170 |
Why?
|
| Subarachnoid Hemorrhage | 4 | 2001 | 140 | 0.170 |
Why?
|
| Lysine | 1 | 2020 | 150 | 0.170 |
Why?
|
| Drug Therapy | 1 | 2020 | 69 | 0.170 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2001 | 171 | 0.170 |
Why?
|
| Intestinal Mucosa | 1 | 2024 | 805 | 0.170 |
Why?
|
| Cerebral Ventricles | 1 | 1999 | 78 | 0.170 |
Why?
|
| Optic Chiasm | 1 | 2019 | 16 | 0.160 |
Why?
|
| Transcription, Genetic | 3 | 2012 | 1158 | 0.160 |
Why?
|
| Fibrinolytic Agents | 1 | 2001 | 217 | 0.160 |
Why?
|
| Paraganglioma | 1 | 2019 | 16 | 0.160 |
Why?
|
| Radiography | 2 | 2013 | 806 | 0.160 |
Why?
|
| Thrombolytic Therapy | 1 | 2021 | 232 | 0.160 |
Why?
|
| Interleukin-12 | 1 | 2019 | 111 | 0.160 |
Why?
|
| DNA | 3 | 2014 | 1309 | 0.160 |
Why?
|
| Carbonic Anhydrase II | 1 | 2018 | 4 | 0.160 |
Why?
|
| Telemedicine | 1 | 2021 | 188 | 0.160 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 247 | 0.150 |
Why?
|
| Astrocytoma | 1 | 2018 | 82 | 0.150 |
Why?
|
| Cerebral Hemorrhage | 1 | 2021 | 341 | 0.150 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 383 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 98 | 0.150 |
Why?
|
| Vasospasm, Intracranial | 4 | 2001 | 35 | 0.150 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 98 | 0.150 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2024 | 511 | 0.150 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 146 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 2499 | 0.140 |
Why?
|
| Dogs | 1 | 2018 | 704 | 0.140 |
Why?
|
| Protein Multimerization | 1 | 2018 | 178 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2018 | 305 | 0.140 |
Why?
|
| Adenoma | 1 | 2019 | 247 | 0.140 |
Why?
|
| Child | 6 | 2022 | 7210 | 0.140 |
Why?
|
| Neuroblastoma | 1 | 2020 | 400 | 0.140 |
Why?
|
| Prognosis | 2 | 2019 | 3777 | 0.140 |
Why?
|
| Radiation, Ionizing | 2 | 2014 | 123 | 0.130 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 846 | 0.130 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 984 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2018 | 870 | 0.130 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 10c | 1 | 2015 | 3 | 0.130 |
Why?
|
| GPI-Linked Proteins | 1 | 2015 | 51 | 0.120 |
Why?
|
| Comet Assay | 1 | 2015 | 9 | 0.120 |
Why?
|
| Disease Management | 1 | 2017 | 326 | 0.120 |
Why?
|
| Kyphosis | 1 | 2014 | 14 | 0.120 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2015 | 73 | 0.120 |
Why?
|
| Gliosis | 1 | 2014 | 35 | 0.120 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2015 | 56 | 0.120 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 139 | 0.120 |
Why?
|
| Longevity | 1 | 2014 | 58 | 0.120 |
Why?
|
| Immunoblotting | 1 | 2015 | 272 | 0.120 |
Why?
|
| Rats | 2 | 2013 | 4040 | 0.120 |
Why?
|
| Combined Modality Therapy | 3 | 2007 | 1705 | 0.110 |
Why?
|
| DNA Primers | 1 | 2015 | 543 | 0.110 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 294 | 0.110 |
Why?
|
| Apoptosis | 2 | 2014 | 1716 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 282 | 0.110 |
Why?
|
| RNA Interference | 1 | 2015 | 376 | 0.110 |
Why?
|
| Pseudotumor Cerebri | 2 | 2004 | 17 | 0.110 |
Why?
|
| Middle Aged | 5 | 2021 | 25971 | 0.110 |
Why?
|
| Heterozygote | 1 | 2014 | 373 | 0.110 |
Why?
|
| Ferric Compounds | 1 | 2013 | 38 | 0.110 |
Why?
|
| Bone and Bones | 1 | 2014 | 271 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 885 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2014 | 520 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 1048 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2021 | 2666 | 0.100 |
Why?
|
| Histones | 1 | 2014 | 332 | 0.100 |
Why?
|
| Nucleotides | 1 | 2012 | 98 | 0.100 |
Why?
|
| Equipment Failure | 3 | 2022 | 120 | 0.100 |
Why?
|
| Skull Base | 2 | 2022 | 48 | 0.100 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1529 | 0.100 |
Why?
|
| Adult | 8 | 2021 | 26659 | 0.090 |
Why?
|
| Brain Diseases | 2 | 2004 | 187 | 0.090 |
Why?
|
| Gene Expression | 1 | 2015 | 1309 | 0.090 |
Why?
|
| Cerebral Angiography | 5 | 2001 | 197 | 0.090 |
Why?
|
| Hematoma | 2 | 2001 | 108 | 0.090 |
Why?
|
| Age Factors | 1 | 2014 | 1876 | 0.090 |
Why?
|
| Genotype | 1 | 2014 | 1852 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2014 | 2021 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2884 | 0.080 |
Why?
|
| Infant | 4 | 2007 | 3173 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 1982 | 0.080 |
Why?
|
| Inflammation | 1 | 2014 | 975 | 0.080 |
Why?
|
| Cranial Fossa, Anterior | 1 | 2008 | 4 | 0.080 |
Why?
|
| Pneumocephalus | 1 | 2008 | 10 | 0.080 |
Why?
|
| Frontal Sinus | 1 | 2008 | 7 | 0.080 |
Why?
|
| Cell Line | 1 | 2012 | 2494 | 0.080 |
Why?
|
| Phenotype | 1 | 2014 | 2447 | 0.080 |
Why?
|
| Subcellular Fractions | 1 | 2007 | 94 | 0.070 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2007 | 137 | 0.070 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2007 | 78 | 0.070 |
Why?
|
| Parietal Bone | 1 | 2007 | 20 | 0.070 |
Why?
|
| Drainage | 1 | 2008 | 165 | 0.070 |
Why?
|
| DNA, Complementary | 1 | 2007 | 391 | 0.070 |
Why?
|
| Neoplasm Transplantation | 1 | 2007 | 397 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2004 | 3753 | 0.070 |
Why?
|
| Fracture Fixation, Internal | 1 | 2007 | 69 | 0.070 |
Why?
|
| Aged | 5 | 2023 | 19124 | 0.070 |
Why?
|
| Craniosynostoses | 1 | 2007 | 77 | 0.070 |
Why?
|
| Frontal Lobe | 1 | 2006 | 132 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2007 | 432 | 0.060 |
Why?
|
| Expert Testimony | 1 | 2005 | 34 | 0.060 |
Why?
|
| Parietal Lobe | 1 | 2006 | 119 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2006 | 294 | 0.060 |
Why?
|
| Sinusitis | 1 | 2008 | 215 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2007 | 1131 | 0.060 |
Why?
|
| Adenoviruses, Human | 1 | 2004 | 41 | 0.060 |
Why?
|
| Monitoring, Ambulatory | 1 | 2004 | 32 | 0.060 |
Why?
|
| Telemetry | 1 | 2004 | 36 | 0.060 |
Why?
|
| Central Nervous System Cysts | 1 | 2004 | 9 | 0.060 |
Why?
|
| Cerebral Arteries | 2 | 2001 | 75 | 0.060 |
Why?
|
| Stroke | 1 | 2022 | 989 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 2015 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2007 | 2375 | 0.050 |
Why?
|
| Tryptophan | 1 | 2022 | 93 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2024 | 387 | 0.050 |
Why?
|
| Cell Survival | 1 | 2004 | 982 | 0.050 |
Why?
|
| Office Visits | 1 | 2021 | 50 | 0.050 |
Why?
|
| Membranes, Artificial | 1 | 2001 | 38 | 0.050 |
Why?
|
| Macaca fascicularis | 4 | 2001 | 108 | 0.050 |
Why?
|
| Adolescent | 3 | 2004 | 9289 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2021 | 169 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2001 | 416 | 0.040 |
Why?
|
| Ferritins | 1 | 2000 | 29 | 0.040 |
Why?
|
| Neoplasms | 2 | 2006 | 3052 | 0.040 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2000 | 44 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2024 | 688 | 0.040 |
Why?
|
| Biopsy | 1 | 2004 | 1183 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2007 | 2303 | 0.040 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2019 | 12 | 0.040 |
Why?
|
| Cysts | 1 | 1999 | 106 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 6761 | 0.040 |
Why?
|
| Thrombosis | 1 | 2001 | 301 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2001 | 314 | 0.040 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 471 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 327 | 0.040 |
Why?
|
| Quality of Life | 1 | 2006 | 1668 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 270 | 0.040 |
Why?
|
| Disease Progression | 2 | 2018 | 1462 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2019 | 342 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 859 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2019 | 448 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2021 | 9097 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 849 | 0.040 |
Why?
|
| Reoperation | 1 | 1999 | 603 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 1727 | 0.030 |
Why?
|
| Early Growth Response Protein 1 | 2 | 2006 | 57 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 642 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1605 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 1353 | 0.030 |
Why?
|
| Mutation | 1 | 2023 | 4158 | 0.020 |
Why?
|
| Prospective Studies | 1 | 1999 | 4305 | 0.020 |
Why?
|
| Hemoglobins | 2 | 2001 | 193 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2007 | 3658 | 0.020 |
Why?
|
| Bone Wires | 1 | 2007 | 13 | 0.020 |
Why?
|
| Genes, MDR | 1 | 2005 | 7 | 0.020 |
Why?
|
| Tumor Necrosis Factors | 1 | 2005 | 14 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2006 | 446 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 563 | 0.010 |
Why?
|
| Length of Stay | 1 | 2007 | 742 | 0.010 |
Why?
|
| Lumbosacral Region | 1 | 2002 | 27 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 2002 | 21 | 0.010 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2002 | 24 | 0.010 |
Why?
|
| Subarachnoid Space | 1 | 2001 | 17 | 0.010 |
Why?
|
| Middle Cerebral Artery | 1 | 2001 | 20 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 2001 | 52 | 0.010 |
Why?
|
| Basilar Artery | 1 | 2001 | 42 | 0.010 |
Why?
|
| Potassium Chloride | 1 | 2001 | 86 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 2001 | 92 | 0.010 |
Why?
|
| Syndrome | 1 | 2002 | 449 | 0.010 |
Why?
|
| Vascular Patency | 1 | 2001 | 129 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2001 | 331 | 0.010 |
Why?
|
| Heme Oxygenase-1 | 1 | 2000 | 19 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2000 | 293 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2001 | 996 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2001 | 899 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 1762 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2004 | 2487 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2004 | 2290 | 0.010 |
Why?
|